arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Beta Bionics, Inc.

BBNX
$15.89 ▲ +1.75 (+12.38%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
12 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Beta Bionics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $707.8M
Dividend Yield
Revenue Growth 37.8%
Op. Margin -79.9%
ROIC -7.9%
FCF / Share $-0.35
Trailing P/E
Price / Book 2.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$32.01M
↑ +37.8%
Net Income Profit after all expenses
$-23.40M
↓ -38.7%
Operating Margin Operating profit as % of sales
-79.9%
↑ +9.1% 3th
FCF / Share Free cash flow per share
$-0.35
↑ +38.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
25
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 12 quarters